Galderma Announces Approval For Differin Gel 0.1 Percent In Japan
Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, has announced that Japan’s Ministry of Health, Labor and Welfare has approved Differin® Gel 0.1% (adapalene), a novel topical treatment for acne vulgaris in Japan. The drug will be marketed in Japan by Galderma KK, the fully-owned Japanese arm of Galderma, and strategic alliance partner Shionogi.
This post is an original post by ScienceDaily: Skin Care News
Posted: July 18th, 2008 under skin health.
Comments: none
Write a comment